このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Spinal Muscular Atrophy and School Transitions

Exploring Educational Transitions in Children and Young People With Spinal Muscular Atrophy: A Qualitative Study of Patient and Family Experiences.

A qualitative questionnaire-based study to explore the experiences of children and young people with Spinal Muscular Atrophy (SMA) and their families regarding school transition and educational participation.

The study objectives:

To identify barriers to successful educational transition. To advocate for patients and families during the transitional process. To explore experiences of inclusion, access and support within school settings. To understand the coordination between education, healthcare and support services.

To inform the development of practical, patient-centred guidance to improve educational transitions for children and young people with SMA.

調査の概要

状態

まだ募集していません

詳細な説明

Neuromuscular diseases (NMDs) are a group of rare heterogeneous conditions which primarily affect the peripheral nervous system and skeletal muscle. Neuromuscular diseases are frequently progressive in nature and lead to increasing muscle weakness and systemic complications. Through advances in diagnosis and multidisciplinary clinical care there have been significant improvements in life expectancy and opportunities to have a fulling life. It is therefore imperative that transition, at all stages of a patient's journey, are supported and provide best opportunities.

It has been recognised for over 10 years that transition from paediatric to adult medical care has been fraught with issues and preparations for transition are often delayed until such time as the patient reaches or nears adult age or ignores completely. This has consequences for poorer outcomes in health and quality of life. Models do exist, but they lack depth and focus on the medical model, and so fault address all the criteria involved in a successful transition. Therefore, the period of transition from paediatric to adult healthcare is a time of uncertainty and stress for those with rare diseases. Both young adults and their parents/carers encounter a wide range of obstacles during the transition period, including poor understanding of the process, difficulty accessing appropriate support, expectations regarding future care and educational or work opportunities. During this transition period factors which exacerbate the stresses encountered are numerous, such as disease specific challenges and a lack of expertise amongst adult health care professionals, and wider care or education providers.

Transition is not merely an administrative process but a time that requires careful targeted multidisciplinary care to ensure that all the needs of a young person with NMDs are met. This not only should include medical transition but also psychological and social requirements. It is suggested that transition should start in young adolescence to prepare both patients and their families for changes in healthcare providers and introduce new teams and roles. Transition should be carefully planned with a patient family centred approach. Poor or inadequately planned transitions could cause negative outcomes related to prognosis of disease, mortality, psychosocial and educational attainment. Blum et al (1993) defines transition as 'the purposeful movement of adolescents with chronic physical and medical conditions from child-centred care to adult oriented healthcare systems'. However, Blum's definition is reductionist in nature and only addresses the health component; transition is better defined as 'the passage from one phase of a person's life, physical condition or social role to another'. And as such this could include transitions from ambulant to non-ambulant, requirement of overnight ventilation, sexual health and puberty, loss of social contacts, social inclusion, and all forms of transitions moving through the education system.

As is evident from the literature available on transition in those with NMD it is primarily focused on the medical transition. Most, if not all the literature suggests that transition starts in young adolescence and introduces the process of moving from paediatric healthcare to adult services.

The transition of those with NMDs when focused on healthcare does not address many areas of the transition that are important to ensure all opportunities are met. One unmet period of transition is that of moving from primary school to senior school, a time of great uncertainty and stress for both the patient and the parents/carers. The United Nations fourth sustainable global development goal is to ensure inclusive and equitable education and promote lifelong learning opportunities for all by 2030. However, those entering upper secondary education is at 86% for the non-disabled and only 66% for those with a disability or psychiatric diagnosis. In addition, those with NMDs are generally absent from school more often when compared to those without, the reasons being general poorer health, greater incidence of anxiety/depression, lack of learning opportunities, poor supportive infrastructure and insufficient compensatory education. It follows that to ensure all young persons with NMDs have access to education to better their quality of life and independence. The risk of not providing or having less than optimal access to education or absence due to appointments or ill health is a strong predictor of how well they will fair in life with regard to health, income, independence, employment, social inclusion and working life conditions.

The United Nations Convention on the Rights of Persons with Disabilities (CRPD) was adopted on 13th December 2006. There are 82 signatories to the Convention, 44 signatories to the Optional Protocol and 1 ratification of the protocol. The Convention has the goal of changing attitudes and approaches to people with disabilities. As part of the CRPS education was seen as an imperative and as such a whole section was devoted to this: Article 24 (see appendix 1 for full details). Article 24 of the CRPD lays out the basic and fundamental rights a disabled person has to a fair and non-discriminatory education with an emphasis on the States Parties to recognise and act so that all are given fair and equal opportunities.

The United Kingdom Government has a Disability Rights Act 2010. Included within that law is the right that protects the disabled from discrimination and provides legal rights including for education, free from direct or indirect discrimination, discrimination arising from disability, harassment, and victimisation. Schools have duty to provide 'reasonable adjustments' to ensure disable students are not discriminated against, however schools are 'not subject to the reasonable adjustment duty to make alterations to physical features, like adding ramps. They must make the buildings accessible for their disabled pupils as part of their overall planning duties'. Conversely, access to education for those with NMDs is not optimal and the transitions from primary school to and during the education journey are fraught with difficulties and barriers.

All NMDs should be approached as unique in their own right when considering transition and approached from a multidisciplinary perspective. The Spinal Muscular Atrophies (SMAs) are one such NMD that is a progressive neurodegenerative condition characterised by a significant and complex disease trajectory. The primary presentation is that of symmetrical proximal muscle weakness and atrophy, with associated loss of function. SMA presents with a broad spectrum of disease severity with classification based on age of onset and motor milestones achieved. SMA type I is the most common subtype, with approximately 42 babies being born each year in the United Kingdom with SMA type I, being symptomatic before age 6 months. Those affected do not achieve independent sitting, although prognosis is now much improved following the introduction of three disease modifying therapies. Those with type II SMA typically develop weakness between ages 6 to 18 months and can sit independently in early years. As the disease progresses the need for respiratory support and orthopaedic presentations, such as scoliosis and hip dysplasia, increase. SMA type III present with symptoms post 18 months and attain independent ambulation, however this may be lost as the disease progresses.

The CI is a member of the direct care team who treats this patient population. He would like to hold an initial focus group with 3 patients and their families to provide a consensus on the developing questionnaire, which will then be sent out to a further 9 patients and their families.

研究の種類

観察的

入学 (推定)

20

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Shropshire
      • Oswestry、Shropshire、イギリス、SY10 7AG
        • The Robert Jones & Agnes Hunt Orthopaedic Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 子
  • 大人

健康ボランティアの受け入れ

いいえ

サンプリング方法

非確率サンプル

調査対象母集団

Participants with a genetic diagnosis of Spinal Muscular Atrophy 1, 11 or 111.

説明

Inclusion Criteria:

  • Genetically confirmed diagnosis of Spinal Muscular Atrophy 1, 11 or 111
  • In education, in either primary school, secondary school or further education
  • Access to internet and either a smart phone, tablet or computer.

Exclusion Criteria:

  • Not in education
  • Not able to comply with the consent process
  • Not cognitively able to complete the questionnaire.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

コホートと介入

グループ/コホート
Focus group
Discussion regarding the development of a questionnaire
Completing questionnaire

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Completion of the questionnaire to explore the experiences of children and young people with SMA and their families regarding school transition and educational participation.
時間枠:1 month to complete the focus groups. 1 month to develop the questionnaire. 1 month to send questionnaires to 12 families and allow for the responses back.
3 families will be invited to take place in a focus group discussion. Each family will be interviewed in a family unit on Microsoft Teams. These discussions will enable the development of a questionnaire which will be sent to 12 families to complete.
1 month to complete the focus groups. 1 month to develop the questionnaire. 1 month to send questionnaires to 12 families and allow for the responses back.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Nicholas Emery、Neuromuscular Clinical Specialist Physiotherapist

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年8月10日

一次修了 (推定)

2026年11月1日

研究の完了 (推定)

2027年2月28日

試験登録日

最初に提出

2026年7月17日

QC基準を満たした最初の提出物

2026年7月17日

最初の投稿 (実際)

2026年7月22日

学習記録の更新

投稿された最後の更新 (実際)

2026年7月22日

QC基準を満たした最後の更新が送信されました

2026年7月17日

最終確認日

2026年7月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する